Brazilian pharmacies sold nearly half a million boxes of weight loss pens in January this year, predominantly to women averaging 47 years of age, with Mounjaro leading in sales.
In January 2026, Brazilian pharmacies reported the sale of nearly 443,815 boxes of weight loss pens, marking a notable trend where women between the ages of 40 and 49 accounted for a substantial proportion of these purchases. The data, sourced from the National System for the Management of Controlled Products (SNGPC), indicates a significant resurgence in the market for these medications after a suspension of reporting requirements since late 2021. This uptick is pivotal given the evolving landscape of weight management and the reintroduction of regulations allowing for the collection of such data.
Mounjaro emerged as a leading product in this category, representing 52.8% of the total weight loss pen sales. Following Mounjaro were Wegovy and other medications, which highlighted a wider trend in preference for GLP-1 agonists, substances that assist in weight loss by activating a particular hormone in the body. This sales data reflects not just a response to consumer demand but also underlines the evolving perceptions of weight loss solutions among Brazilian women.
The implications of these findings are multifaceted. As the market for weight loss medications continues to expand, fueled by growing consumer interest, it raises questions about public health, accessibility of these treatments, and the ongoing discourse surrounding weight loss in Brazil. This trend, particularly among middle-aged women, suggests a shift in societal attitudes toward weight management and poses the necessity for healthcare professionals to engage more comprehensively with patients regarding treatment options and holistic health plans.
